We found that low sensitivity to the MEK inhibitors trametinib and binimetinib observed in some MM cell lines, including CAG and U266 with RAF-1 (CRAF) and BRAF mutations (see Figure 1A), could possibly be explained by high basal expression levels of phospho-TBK1 and Bcl-2 proteins. Here, MAP2K7 is linked to Miyoshi myopathy.